Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

SNSE 11.27.2024

Full Press ReleaseSEC FilingsOur SNSE Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
  • 11.27.2024 - Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference
  • 11.14.2024 - Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Recent Filings

  • 01.07.2025 - 8-K Current report
  • 12.23.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.14.2024 - EX-99.1 EX-99.1
PDF Version

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.

About Sensei BiotherapeuticsSensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAbTM (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visitwww.senseibio.com, and follow the company on X @SenseiBio andLinkedIn.

Investor Contact:Michael BiegaSenior Director, Investor RelationsSensei Biotherapeuticsmbiega@senseibio.com

Media Contact:Joyce AllaireLifeSci AdvisorsJallaire@lifesciadvisors.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com